Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer

The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy. The main questions it aims to answer are: * 5-year disease-free survival * 5-year overall survival * 5-year locoregional recurrence * Adverse events after radiation therapy * Quality of life Participants will be assessed by multi-dimensional methods before and after radiotherapy: * Disease status evaluation including physica

Trial Details

NCT ID

NCT05896865

Phase

NA

Sponsor

Samsung Medical Center

Status

RECRUITING

Cancer Type

Breast Cancer

Locations (sample)

• Seoul, South Korea

Key Eligibility Criteria

• Female with age 19 or older
• Metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy
• Underwent neoadjuvant chemotherapy
• Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →